Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia.

Sci Rep · 2022 · PMC9508266 · PMID 36151238

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Of note, OX40 high subjects after ASCT showed a trend towards a shorter OS comparted to OX40 low subjects ( p -value 0.061, HR 0.33, 95% CI 0.10–1.14) (Fig. 3 e).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.